15
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T7406 | AKR1C3-IN-1 | NADPH | |
AKR1C3-IN-1 is a potent and selective inhibitor of AKR1C3(IC50 of 13 nM). | |||
T38684 | AKR1C3-IN-4 | AKR1C3-IN-4 | NADPH |
AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research. | |||
T67846 | AKR1C3-IN-9 | NADPH | |
AKR1C3-IN-9 is a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50= 8.92 nM). AKR1C3-IN-9 can significantly reverse the Doxorubicin (DOX) resistance in a resistant breast cancer cell line. | |||
T61925 | AKR1C3-IN-7 | ||
AKR1C3-IN-7 (Compound 13) is an effective and selective AKR1C3 inhibitor (IC50=0.19 μM). AKR1C3-IN-7 has antitumor activity. | |||
T79433 | AKR1C3-IN-10 | ||
AKR1C3-IN-10 (compound 5r), a selective inhibitor of AKR1C3 with an IC50 of 51 nM, demonstrates efficacy in a prostate cancer xenograft model [1]. | |||
T64193 | AKR1C3-IN-5 | ||
AKR1C3-IN-5 (Compound 6e) is a potent inhibitor of AKR1C3, derived from drupanin. AKR1C3 enzymes are overexpressed in hormone-dependent prostate and breast tumours. AKR1C3-IN-5 is able to act on MCF-7 cells (IC50: 9.6 ± ... | |||
T61926 | AKR1C3-IN-8 | ||
AKR1C3-IN-8 (Compound 5) is an effective and selective AKR1C3 inhibitor (IC50=0.069 μM). AKR1C3-IN-8 has antitumor activity. | |||
T61790 | AKR1C3-IN-6 | ||
AKR1C3-IN-6 (Compound 1) is a powerful and specific inhibitor of AKR1C3, with IC50 values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. It demonstrates significant antitumor activity [1]. | |||
T67950 | S19-1035 | NADPH | |
S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research. | |||
T27990 | MDK-0738 | AKR1C3-IN-14a,AKR1C3 IN 14a | |
MDK-0738 is a potent and selective aldo-keto reductase 1C3 inhibitor. | |||
T26196 | SN34037 | SN-34037,SN 34037 | |
SN34037 is a specific Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) inhibitor. | |||
T61003 | S07-2009 | ||
S07-2009 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) (IC 50 = 0.20 μM) [1]. | |||
T61033 | S07-2001 | ||
S07-2001 enhances Doxorubicin against cancer cells activity, which can be used as a chemotherapeutic potentiator for cancer drug resistance. S07-2001 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3... | |||
T61511 | S07-2005 (racemic) | ||
S07-2005 racemic is a chemically potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. Due to its inhibitory properties, it exh... | |||
T78199 | S07-1066 | Others | |
S07-1066, an aldo-keto reductase 1C3 (AKR1C3) inhibitor, enhances doxorubicin (DOX) cytotoxicity by selectively inhibiting AKR1C3-mediated reduction of DOX and reversing DOX resistance in cells with elevated AKR1C3 expre... |